Synergistic healing: harnessing snail mucus enriched with carob extract for anti‐inflammatory and antioxidant therapy in ulcerative colitis

Inflammatory bowel diseases (IBD), including ulcerative colitis, are characterized by chronic inflammation and oxidative stress, necessitating novel therapeutic approaches. This study explores the therapeutic potential of snail mucus derived from snails fed different concentrations of carob (SSCS) and compares its efficacy to aqueous carob extracts (AECS). Both SSCS and AECS are rich in bioactive compounds with potential anti-inflammatory, antioxidant and tissue-regenerative effects. Snail mucus was found to be rich in collagen and allantoin, which are crucial for tissue repair and cell regeneration, whereas carob extracts contained high levels of phenolics, tannins and flavonoids, contributing to their antioxidant properties. In a rat model of acetic acid-induced ulcerative colitis, pretreatment with SSCS, AECS or sulfasalazine significantly alleviated colonic damage. The SSCS30% group exhibited the strongest protective effects, comparable to sulfasalazine, in reducing mucosal injury, inflammation and immune activation. Biochemical analyses demonstrated that SSCS30% effectively decreased systemic inflammation markers (CRP), pancreatic stress indicators (amylase) and liver enzyme levels (AST, ALT, ALP), while enhancing antioxidant defenses and preserving colonic sulfhydryl content. These findings underscore the therapeutic potential of snail mucus, particularly from snails fed a 30% carob-enriched diet, as a promising natural therapy for IBD. Its potent anti-inflammatory, antioxidant and tissue-regenerative properties suggest that the use of SSCS30% could serve as an innovative approach for managing ulcerative colitis and other inflammatory disorders. These findings suggest that carob-enriched snail mucus could serve as a complementary therapy for ulcerative colitis patients, though clinical validation remains necessary. While these preclinical results are promising, further clinical studies are needed to validate the therapeutic potential of this natural combination in human ulcerative colitis. © 2025 Society of Chemical Industry.